Smartlab Europe

Agilent Technologies and Oxford Gene Technology Expand Microarray and Sequencing Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...
- Advertisement -

Agilent Technologies Inc. and Oxford Gene Technology today announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.

Mike Evans, chief executive of OGT, said: “We are delighted to have been able to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”

“Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program,” said Robert Schueren, vice president and general manager of Agilent’s genomics business. “OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”

Latest stories

Related stories

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »